Agios Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di Agios Pharmaceuticals diminuiranno a 56.7% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 55.4% all'anno. Si prevede che l'EPS diminuirà di 57.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà -21% in 3 anni.

Informazioni chiave

-56.7%

Tasso di crescita degli utili

-57.7%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	0%
Tasso di crescita dei ricavi	55.4%
Rendimento futuro del capitale proprio	-21.0%
Copertura analitica	Good
Ultimo aggiornamento	06 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

BMV:AGIO * - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	176	-317	-251	-315	8
12/31/2025	92	-360	-249	-321	10
12/31/2024	35	673	-299	-303	10
9/30/2024	33	674	-330	-329	N/A
6/30/2024	31	-365	-325	-307	N/A
3/31/2024	29	-353	-319	-301	N/A
12/31/2023	27	-352	-315	-296	N/A
9/30/2023	24	-220	-308	-290	N/A
6/30/2023	20	-210	-300	-299	N/A
3/31/2023	19	-218	-309	-307	N/A
12/31/2022	14	-232	-314	-309	N/A
9/30/2022	10	-367	-337	-327	N/A
6/30/2022	6	-369	-350	-341	N/A
3/31/2022	1	-360	-392	-384	N/A
12/31/2021	N/A	-357	-413	-407	N/A
9/30/2021	N/A	-342	-374	-373	N/A
6/30/2021	N/A	-337	-363	-356	N/A
3/31/2021	N/A	-336	-317	-306	N/A
12/31/2020	N/A	-329	-305	-291	N/A
9/30/2020	35	-347	-355	-335	N/A
6/30/2020	61	-374	-370	-352	N/A
3/31/2020	88	-402	-387	-373	N/A
12/31/2019	N/A	-301	-383	-371	N/A
9/30/2019	112	-401	-358	-351	N/A
6/30/2019	102	-389	-337	-329	N/A
3/31/2019	116	-348	-316	-309	N/A
12/31/2018	94	-346	-311	-304	N/A
9/30/2018	74	-343	-312	-305	N/A
6/30/2018	70	-325	N/A	-319	N/A
3/31/2018	41	-339	N/A	-310	N/A
12/31/2017	43	-315	N/A	-285	N/A
9/30/2017	56	-283	N/A	-262	N/A
6/30/2017	53	-269	N/A	-233	N/A
3/31/2017	49	-241	N/A	-17	N/A
12/31/2016	70	-198	N/A	39	N/A
9/30/2016	53	-183	N/A	59	N/A
6/30/2016	50	-160	N/A	83	N/A
3/31/2016	56	-136	N/A	-70	N/A
12/31/2015	59	-118	N/A	-77	N/A
9/30/2015	68	-104	N/A	-54	N/A
6/30/2015	96	-60	N/A	-53	N/A
3/31/2015	91	-46	N/A	-58	N/A
12/31/2014	65	-54	N/A	-59	N/A
9/30/2014	57	-39	N/A	-65	N/A
6/30/2014	30	-55	N/A	-57	N/A
3/31/2014	28	-47	N/A	-71	N/A
12/31/2013	26	-44	N/A	-56	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di AGIO * diminuiranno nei prossimi 3 anni ( -56.7% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di AGIO * diminuiranno nei prossimi 3 anni ( -56.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di AGIO * diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di AGIO * ( 55.4% all'anno) crescerà più rapidamente del mercato MX ( 7.2% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di AGIO * ( 55.4% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che AGIO * non sarà più redditizia tra 3 anni.

Agios Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Recent updates

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Insufficient new directors

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.

Agios Pharmaceuticals, Inc. Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Agios Pharmaceuticals, Inc. Launches Anemia ID

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Third quarter 2020 earnings released: US$1.43 loss per share

Revenue misses expectations

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals, Inc. Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita